News

November 15, 2023

Inhalon Biopharma Secures U.S. Army Medical Research and Development Command Award to Support Development of Inhaled Therapeutics for Treatment of COVID-19  Read More

​

November 1, 2023

Inhalon Biopharma Expands Therapeutic Horizons with Licensing of hMPV Antibodies from the University of Georgia  Read More

​

October 6, 2023

Inhalon Biopharma to Share Progress in Development of Inhaled Antibody Platform at the Bio Investor Forum and Bio Europe  Read More

​

June 30, 2022

Inhalon Biopharma Closes Series A Financing to Further their Study of Inhaled Antibodies  Read More

​

October 7, 2021

Inhalon Doses First Patient in Phase 1 Study of Inhaled IN‑006 to Treat COVID-19  Read More

​

July 22, 2021

Inhalon Collaborates with Celltrion, Inc. to Develop Nebulized Form of Regdanvimab to Treat COVID-19 Patients at Home  Read More

​

July 16, 2021

Inhalon Biopharma Appoints Jeff Hutchins, Ph.D. as Chief Development Officer  Read More

​

May 26, 2021

Inhalon Biopharma Receives $7 Million from USAMRDC to Study Inhaled “Muco-trapping” Antibody for the Treatment of COVID-19  Read More